Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc.verified

RNA

Price:

$12.37

Market Cap:

$211.60M

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

Industry

Biotechnology

IPO Date

2026-02-27

Stock Exchange

NASDAQ

Ticker

RNA

The PE Ratio as of June 2026 (TTM) for Atrium Therapeutics, Inc. (RNA) is -2.46

According to Atrium Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.46. This represents a change of 55.36% compared to the average of -1.58 of the last 4 quarters.

Atrium Therapeutics, Inc. (RNA) Historical PE Ratio (quarterly & annually)

How has RNA PE Ratio performed in the past?

The mean historical PE Ratio of Atrium Therapeutics, Inc. over the last ten years is -3.29. The current -2.46 PE Ratio has changed 7.37% with respect to the historical average. Over the past ten years (40 quarters), RNA's PE Ratio was at its highest in in the September 2025 quarter at 0. The PE Ratio was at its lowest in in the March 2026 quarter at -3.44.

Quarterly (TTM)
Annual

Average

-3.29

Median

-3.29

Minimum

-3.29

Maximum

-3.29

Atrium Therapeutics, Inc. (RNA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Atrium Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0%

Maximum Annual PE Ratio = -3.29

Minimum Annual Increase = 0%

Minimum Annual PE Ratio = -3.29

Quarterly (TTM)
Annual
YearPE RatioChange

Atrium Therapeutics, Inc. (RNA) Average PE Ratio

How has RNA PE Ratio performed in the past?

The current PE Ratio of Atrium Therapeutics, Inc. (RNA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-3.29

5-year avg

-3.29

10-year avg

-3.29

Atrium Therapeutics, Inc. (RNA) PE Ratio vs. Peers

How is RNA’s PE Ratio compared to its peers?

Atrium Therapeutics, Inc.’s PE Ratio is

CompanyPE RatioMarket cap

Build a custom stock screener for Atrium Therapeutics, Inc. (RNA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Atrium Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Atrium Therapeutics, Inc. (RNA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Atrium Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Atrium Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Atrium Therapeutics, Inc. (RNA)?

What is the highest PE Ratio for Atrium Therapeutics, Inc. (RNA)?

What is the 3-year average PE Ratio for Atrium Therapeutics, Inc. (RNA)?

What is the 5-year average PE Ratio for Atrium Therapeutics, Inc. (RNA)?

How does the current PE Ratio for Atrium Therapeutics, Inc. (RNA) compare to its historical average?